Carboxymethyl benzylamide sulfonate dextrans (CMDBS), a family of biospecific polymers endowed with numerous biological properties: A review

Journal of Biomedical Materials Research

Volumn 48, Issue 4, 1999, Pages 578-590

  Logeart Avramoglou, Delphine ^a,b   Jozefonvicz, Jacqueline ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b CNRS   (France)

Author keywords

Biomimetic biomaterials; Functionalized dextran; Heparin like properties

Indexed keywords

BIOSYNTHESIS; BLOOD; CELLS; COAGULATION; MACROMOLECULES; METABOLISM; POLYSACCHARIDES; PROTEINS;

BIOACTIVITY; BIOSPECIFICITY; CARBOXYMETHYL BENZYLAMIDE SULFONATE DEXTRANS; HEPARIN;

BIOMATERIALS;

ANTICOAGULANT AGENT; CARBOXYMETHYL BENZYLAMIDE SULFONATE DEXTRAN; POLYMER; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; CHEMICAL COMPOSITION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW;

EID: 0032810028     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4636(1999)48:4<578::AID-JBM26>3.0.CO;2-8     Document Type: Review

References (129)

1. Mauzac M, Jozefonvicz J. Anticoagulant activity of dextran derivatives. Part I: synthesis and characterization. Biomaterials 1984;5:301-304.
2. Huynh R, Chaubet F, Jozefonvicz J. Carboxymethylation of dextran in aqueous alcohol as the first step of the preparation of derivatized dextrans. Angew Makromol Chem 1998;254:61-65.
3. Maiga-Revel O, Chaubet F, Jozefonvicz J. New investigations on heparin-like derivatized dextrans: CMDBS, synergistic role of benzylamide and sulfate substituents in anticoagulant activity. Carbohydr Polym 1997;32:89-93.
4. Krentsel L, Chaubet F, Rebrov A, et al. Anticoagulant activity of functionalized dextrans. Structure analyses of carboxymethylated dextran and first Monte Carlo simulations. Carbohydr Polym 1997;33:63-71.
5. Krentsel LB, Ermakov IV, Yashin VV, et al. Anticoagulant activity of functionalized dextrans. Structure analyses of carboxymethylated dextran and first Monte Carlo simulations. J Polym Sci Ser A 1997;39:74-80.
6. Mauzac M, Fougnot C, Jozefonvicz J. New antithrombogenic polysaccharides. Proc Third Annu Mtg Int Soc Artif Organs 1981;5(Suppl).
7. Rosenberg RD, Damus RD. Purification and mechanism of action of human thrombin-heparin cofactor. J Biol Chem 1973; 18:6490-6505.
8. Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993;289:313-330.
9. Tollefsen DM, Marjerus DW, Blank MK. Heparin cofactor II. J Biol Chem 1982;257:2162-2169.
10. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116:492-499.
11. Roden L. Highlights in the history of heparin. In: Lane DA, Lindahl U, editors. Heparin chemical and biological properties, clinical applications. London: Edward Arnold; 1989. p 1-23.
12. Tollefsen DM. The interaction of glycosaminoglycans with heparin cofactor II. Ann NY Acad Sci 1994;16:98-204.
13. Church FC, Meade JB, Treanor RE, Whinna HC. Antithrombotic activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III and thrombin. J Biol Chem 1989;264:3618-3623.
14. Yates EA, Santini F, Guerrini M, Naggi A, Torri G, Casu B. 1H and 13C NMR spectral assignments of the major sequences of twelve systematically modified heparin derivatives. Carbohydr Res 1996;20:15-27.
15. Sakamoto N, Kishida A, Maruyama I, Akashi M. The mechanism of anticoagulant activity of a novel heparinoid sulfated glucoside-bearing polymer. J Biomater Sci Polym Ed 1997;8: 548-553.
16. Mauzac M, Aubert N, Jozefonvicz J. Antithrombic activity of some polysaccharide resins. Biomaterials 1982;3:221-224.
17. Aubert N, Mauzac M, Gulino D, Jozefonvicz J. Anticoagulant hydrogels derived from crosslinked dextran: Part II: mechanism of thrombin inactivation. Biomaterials 1987;8:100-104.
18. Fransson LA, Aspinall GO, editors. The polysaccharides, Volume 3. New York: Academic Press; 1985. p 337-415.
19. Crépon B, Maillet F, Kazachkine MD, Jozefonvicz J. Molecular weight dependency for the acquired anticomplementary and anticoagulant activities of specifically substituted dextrans. Biomaterials 1987;8:248-253.
20. Fischer AM, Mauzac M, Tapon-Bredaudière J, Jozefonvicz J. Anticoagulant activity of dextran derivatives. Part II: mechanism of thrombin inactivation. Biomaterials 1985;6:198-202.
21. Maaroufi MR, Jozefowicz M, Tapon-Bretaudière J, Jozefonvicz J, Fischer AM. Mechanism of thrombin inibition by heparin cofactor II in the presence of dermatan sulfates, native or oversulfated, and a heparin-like dextran derivative. Biomaterials 1997;18:359-366.
22. Mauray S, De Raucourt E, Chaubet F, Maïga-Revel O, Sternberg C, Fischer AM. Comparative anticoagulant activity and influence on thrombin generation of dextran derivatives and of a fucoidan fraction. J Biomater Sci Polym Ed 1998;9:373-387.
23. Lormeau JC, Herault JP. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic AT III-binding pentasaccharide. Thromb Haemost 1995;69:152-156.
24. Herbert JM, Herault JP, Bernat A, et al. Biochemical and pharmacological properties of Sanorg 32701. Circ Res 1996;79: 590-600.
25. De Raucourt E, Mauray S, Chaubet F, Maiga-Revel O, Jozefonvicz J, Fischer AM. Anticoagulant activity of dextran derivatives. J Biomed Mater Res 1998;41:49-57.
26. Chaubet F, Champion J, Maïga O, Mauray S, Jozefonvicz J. Synthesis and structure-anticoagulant property relationships of functionalized dextrans: CMDBS. Carbohydr Polym 1995;18: 145-152.
27. Jozefonvicz J, Jozefowicz M. Interactions of biospecific functional polymers with blood proteins and cells. J Biomater Sci Polym Ed 1990;1:147-165.
28. Kinoshita T. Biology of the complement: the overture. Immunol Today 1991;12:291-342.
29. Dalmasso AP. Complement in the pathophysiology and diagnosis of human diseases. Crit Rev Clin Lab Sci 1991;24:123-183.
30. Anderson JM. Inflammatory response to implants. ASAIO J 1988;11:101-107.
31. Kazatchkine MD, Carreno MP. Activation of the complement system at the interface between blood and artificial surfaces. Biomaterials 1988;9:30-35.
32. Montdargent B, Toufik J, Carreno MP, Labarre D, Jozefowicz M. Complement activation and adsorption of protein fragments by functionalized polymer surfaces in human serum. Biomaterials 1992;13:571-576.
33. Maillet F, Kazatchkine MD. Specific antibodies enhance alternative complement pathway activation by cuprophane. Nephrol Dial Transplant 1991;6:193-197.
34. Weiler JM, Yurt RW, Fearon DT, Austen KF. Modulation of the formation of the amplification convertase of complement C3bBb by native and commercial heparin. J Exp Med 1978; 147:409-421.
35. Maillet F, Kazatchkine MD, Glotz D, Fischer E, Rowe M. Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b. Mol Immunol 1983;20:1401-1404.
36. Kazatchkine MD, Fearon DT, Silbert JE, Austen KF. Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med 1979;150:1202-1215.
37. Kazatchkine MD, Fearon DT, Medcalf DD, Rosenberg RD, Austen KF. Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase. J Clin Invest 1981;67:223-228.
38. Maillet F, Petitou M, Choay J, Kazatchkine MD. Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and the anti-complementary sites on the heparin molecule. Mol Immunol 1988;25:917-923.
39. Mauzac M, Maillet F, Jozefonvicz J, Kazatchkine MD. Anti-complementary activity of dextran derivatives. Biomaterials 1985;6:1961-1963.
40. Thomas H, Maillet F, Letourneur D, Jozefonvicz J, Kazatchkine MD. Substitued dextran derivative inhibits complement activation in vivo. Biomaterials 1995;16:1163-1167.
41. Carreno MP, Labarre D, Jozefowicz M, Kazatchkine MD. The ability of Sephadex to activate human complement is suppressed in specifically substituted functional Sephadex derivatives. Mol Immunol 1988;25:165-171.
42. Dalmasso AP, Platt JL. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation 1993;56:1171-1176.
43. Platt JL, Fischel RJ, Matas AJ, Reif SA, Morton Bolman R, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991;52:214-220.
44. Dalmasso AP, Falk RJ, Raij L. The pathobiology of the terminal complement complexes. Complement Inflamm 1989;6:36-48.
45. Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunol Today 1991;12:322-326.
46. Thomas H, Maillet F, Letourneur D, Jozefonvicz J, Fischer E, Kazatchkine MD. Sulfonated dextran inhibits complement-dependent cytotoxicity in an in vitro model of hyperacute xenograft rejection. Mol Immunol 1996;33:643-648.
47. Christensen GD, Baldassari L, Simpson WA. Colonization of medical devices by coagulase-negative staphylococci. In: Bisno AL, Waldvogel FA, editors. Infections associated with indwelling medical devices. Washington, DC: ASM Press; 1994. p 45-78.
48. Vaudaux P, Suzuki R, Waldvogel FA, Morgenthalet JJ, Nydegger UE. Foreign body infection: role of fibronectin as a ligand for the adherence of Staphylococcus aureus. J Infect Dis 1984; 150:546-553.
49. Vaudaux P, Lerch P, Velazco MI, Nydegger UE, Waldvogel FA. Role of fibronectin in the susceptibility of biomaterial implants to bacterial infections. In: Christel P, Meunier A, Lee AJ, editors. Biological and biomechanical performances of biomaterials. Amsterdam: Elsevier Science Publishers, B.V.; 1986. p 387-402.
50. Herrmann M, Vaudaux P, Pittet D, et al. Fibronectin, fibrinogen and laminin act as mediators of clinical Staphylococcal isolates to foreign material. J. Infect. Dis. 158:693-701, 1988.
51. Ruoslahti E. Fibronectin and its receptors. Annu Rev Biochem 1988;57:375-413.
52. Yamada KM. Fibronectin domains and receptors. In: Mosher DF, editor. Biology of extracellular matrix: a series, fibronectin. San Diego, CA: Academic Press; 1989.
53. Hay ED. Cell biology of extracellular matrix. New York: Plenum Press; 1991.
54. Vaudaux P, Yasuda H, Velazco MI, et al. Role of host and bacterial factors in modulating staphylococcal adhesion to implanted polymer surfaces. J Biomater Applic 1990;5:134-153.
55. Vaudaux P, Avramoglou T, Letourneur D, Lew DP, Jozefonvicz J. Inhibition by heparin and derivatized dextrans of Staphylococcus aureus adhesion to fibronectin-coated biomaterials. J Biomater Sci Polym Ed 1992;4:89-97.
56. Neyts J, Reymen D, Letourneur D, et al. Differential antiviral activity of derivatized dextrans. Biochem Pharmacol 1995;50: 743-751.
57. Klatzmann DR, McDougal JS, Maddon PJ. The CD4 molecule and HIV infection. Immunodefic Rev 1990;2:43-66.
58. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996;381:667-673.
59. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996;384:179-183.
60. Auterio M, Abrescia P, Dettin M, Di Bello C, Guardiola J. Binding to CD4 of synthetic peptides patterned on the principal neutralizing domain of HIV-1 envelope protein. Virology 1991; 185:820-828.
61. Benjouad A, Seddiki N, Ylisastigui L, Gluckman JC. HIV type 1 V3 peptide constructs act differently on HIV type 1 infection of peripheral blood lymphocytes and macrophages. AIDS Res Hum Retroviruses 1996;13:257-263.
62. Ivanoff LA, Dubay JV, Morris JF, et al. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus entry. Virology 1992;187:423-432.
63. Batinic D, Robey FA. The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. J Biol Chem 1992;267:6664-6671.
64. De Clercq E. Potential drugs for the treatment of AIDS. J Antimicrob Chemother 1989;23:5-46.
65. Seddiki N, Mbemba E, Letourneur D, et al. Antiviral activity of derivatized dextrans on HIV-1 infection of primary macrophages and blood lymphocytes. Biochem Biophys Acta 1997; 1362:47-55.
66. Carré V, Mbemba E, Letourneur D, Jozefonvicz J, Gattegno L. Interactions of HIV-1 envelope glycoproteins with derivatized dextrans. Biochim Biophys Acta 1995;1243:175-180.
67. Rausch DM, Hwang KM, Padgett M, et al. Peptides derived from the CDR″-homologous domain of the CD4 molecule are specific inhibitors of HIV-1 and SIV infection, virus induced cell fusion, and post-infection viral transmission in vitro. Implications for the design of small peptide anti-HIV therapeutic agents. Ann NY Acad Sci 1990;616:125-148.
68. Elias CJ, Heise LL. Challenges for the development of female controlled vaginal microbicides. AIDS 1994;8:1-9.
69. Grotendorst GR. Chemoattractants and growth factors. In: Cohen IK, Diegelmann RF, Lindblad WJ, editors. Wound healing: biochemical and clinical aspects. Philadelphia, PA: W.B. Saunders; 1992.
70. Flaumenhaft R, Moscatelli D, Saksela O, Rifkin D. Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis. J Cell Physiol 1989;140:75-81.
71. Ruoslahti E, Yamaguchi D. Proteoglycans as modulators of growth factor activities. Cell 1991;64:867-869.
72. Saksela O, Moscatelli D, Sommer A, Rifkin B. Endothelial cell-derived heparin sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988; 107:743-751.
73. Wight TN, Kinsella MG, Qwarnström EE. The role role of proteoglycans in cell adhesion, migration and proliferation. Curr Opin Cell Biol 1992;4:793-801.
74. Goa KL, Benfield P. Hyaluronic acid. A review of its pharmacology and use as a surgical aid in ophthalmology, and its therapeutic potential in joint disease and wound healing. Drugs 1994;47:536-566.
75. Urmann B, Gomel V, Jetha N. Effect of hyaluronic acid on post-operative intraperitoneal adhesion prevention in the rat model. Fertil Steril 1991;56:563-567.
76. Locci P, Marinucci L, Lilli C, Martinese D, Becchetti E. Transforming growth factor beta 1-hyaluronic acid interaction. Cell Tissue Res 1995;281:317-324.
77. Coltrini D, Rusnati M, Zoppetti G, et al. Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. Eur J Biochem 1993;214:51-58.
78. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986;128:475-484.
79. Sommer A, Rifkin DB. Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J Cell Physiol 1989;138:215-220.
80. Tardieu M, Slaoui F, Jozefonvicz J, Courty J, Gamby C, Barritault D. Biological and binding studies of acidic fibroblast growth factor in the presence of substituted dextran. J Biomater Sci Polym Ed 1989;1:63-70.
81. Tardieu M, Gamby C, Avramoglou T, Jozefonvicz J, Barritault D. Derivatized dextrans mimic heparin as stabilizers, potentiators, and protectors of acidic or basic FGF. J Cell Physiol 1992;150:194-203.
82. Meddahi A, Benoit J, Ayoub N, Sézeur A, Barritault D. Heparin-like polymers derived from dextran enhance colonic anastomosis resistance to leakage. J Biomed Mater Res 1996;31: 293-297.
83. Meddahi A, Blanquaert F, Saffar JL, et al. New approaches to tissue regeneration and repair. Pathol Res Commun 1994;190: 923-928.
84. Blanquaert F, Saffar JL, Colombier ML, Carpentier G, Barritault D, Caruelle JP. Heparin-like molecules induce the repair of skull defects. Bone 1995;17:499-506.
85. Lafont J, Baroukh B, Meddahi A, Caruelle JP, Barritault D, Saffar JL. Derivatized dextrans (CMDBS) as promoters of bone healing. Factors influencing their effectiveness. Cell Mater 1994;4:219-230.
86. Gautron J, Kedzia C, Husmann I, Barritault D. Injection of a heparan sulfate like substance in a crushed muscle accelerates its regeneration. C R Acad Sci Paris Life Sci 1995;318:671-676.
87. Fredj-Reygrobellet D, Hristova D, Ettaiche M, Maddahi A, Jozefonvicz J, Barritault D. CMDBS, functional analogue of heparin sulfate as a new class of corneal ulcer healing agents. Ophthal Res 1994;26:325-331.
88. Meddahi A, Lemdjabar H, Caruelle JP, Barritault D, Hornebeck W. FGF protection and inhibition of human neutrophil elastase by carboxymethyl benzylamide sulfonate dextran derivatives. Int J Biol Macromol 1996;18:141-145.
89. Meddahi A, Lemdjabar H, Caruelle JP, Barritault D, Hornebeck W. Inhibition by dextran derivatives of FGF-2 plasmin-mediated degradation. Biochimie 1995;77:703-706.
90. Sudhalter J, Folkman J, Svahn CM, Bergendal K, D'Amore PA. Importance of size, sulfation, and anticoagulant activity in the potentiation of acidic fibroblast growth factor by heparin. J Biol Chem 1989;264:6892-6897.
91. Berrada S, Amedée J, Avramoglou T, Jozefonvicz J, Harmand MF. Effect of a derivatized dextran on human osteoblast growth and phenotype expression. J Biomater Polym Ed 1994;6:211-222.
92. Rosenberg RD, Fritze LMS, Castellot JJ, Karnovsky MJ. Heparin-like molecules as regulators of atherogenesis. Nouv Rev Fr Hematol 1984;26:225-260.
93. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res 1986;46:467-473.
94. Sakamoto N, Tanaka NG, Tohgo A, Osada Y, Ogawa H. Inhibitory effects of heparin plus cortisone acetate on endothelial cell growth both in cultures and in tumor masses. J Natl Cancer Inst 1987;78:581-585.
95. Thompson RW, Orlidge A, D'Amore PA. Heparin and growth control of vascular cells. Purification and properties a heparin-dependant inhibitor of thrombin in human plasma. Ann NY Acad Sci 1989;556:255-267.
96. Bârzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochem Biophys Acta 1985;845:196-203.
97. Castellot JJ, Wong K, Herman B, et al. Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 1985;124:13-20.
98. Letourneur D, Champion J, Slaoui F, Jozefonvicz J. In vitro stimulation of human endothelial cells by derivatized dextrans. In Vitro Cell Dev Biol 1993;29:67-72.
99. Schwartz SM, Liaw L. Growth control and morphogenesis in the development and pathology of arteries. J Cardiovasc Pharmacol 1993;21:31-49.
100. Clowes AW, Karnovsky MJ. Suppression by heparin of smooth muscle cell proliferation in the injured arteries. Nature 1977;265:625-636.
101. Benitz WE, Kelley T, Anderson CM, Lorant DE, Bernfield M. Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation. Am J Respir Cell Mol Biol 1990;2:13-24.
102. Guyton JR, Rosenberg RD, Clowes AW, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res 1980;46:625-634.
103. Hoover RL, Rosenberg RD, Haering W, Karnovsky MJ. Inhibition of rat arterial smooth muscle cell proliferation by heparin. II: in vitro studies. Circ Res 1980;47:578-583.
104. Logeart D, Avramoglou T, Jozefonvicz J. Functional dextrans inhibit rat arterial smooth muscle cell growth in vitro. Colloids Surfaces B Biointerfaces 1994;2:315-322.
105. Castellot JJ, Cochran DL, Karnovsky MJ. Effects of heparin on vascular smooth muscle cells. I: cell metabolism. J Cell Physiol 1985;124:21-28.
106. Letourneur D, Logeart D, Avramoglou T, Jozefonvicz J. Antiproliferative capacity of synthetic dextrans on smooth muscle cell growth: the model of derivatized dextrans as heparin-like polymers. J Biomater Sci Polym Ed 1993;4:431-444.
107. Avramoglou T, Jozefonvicz J. Derivatized dextran inhibition of smooth muscle cell proliferation. J Biomater Sci Polym Ed 1991;3:149-154.
108. Castellot JJ, Choay J, Lormeau JC, Petitou M, Sache E, Karnovsky MJ. Structural determinants of the capacity of heparin to inhibit the proliferation of SMCs. II: evidence for a pentasaccharide sequence that contains a 3-O-sulfate group. J Cell Biol 1986;102:1979-1984.
109. Castellot JJ, Beeler DL, Rosenberg RD, Karnovsky MJ. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol 1984;120:315-320.
110. Wright TC, Castellot JJ, Petitou M, Lormeau JC, Choay J, Karnovsky MJ. Structural determinants of heparin's growth inhibitory activity: interdependency of oligosaccharide size and charge. J Biol Chem 1989;264:1534-1542.
111. Vischer P, Buddecke E. Different action of heparin and fucoidan on arterial smooth muscle cell proliferation and thrombospondin and fibronectin metabolism. Eur J Cell Biol 1991; 56:407-414.
112. Logeart D, Prigent-Richard S, Jozefonvicz J, Letourneur D. Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. Part I. Comparison with heparin for the antiproliferative activity, binding and internalization. Eur J Cell Biol 1997;74:376-384.
113. Logeart D, Prigent-Richard S, Boisson-Vidal C, et al. Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. Part II. Degradation and molecular effect. Eur J Cell Biol 1997;74:385-390.
114. Miao HQ, Ishai-Michaeli R, Peretz T, Vlodavsky I. Laminarin sulfate mimics the effects of heparin on smooth muscle cell proliferation and basic fibroblast growth factor-receptor binding and mitogenic activity. J Cell Physiol 1995;164:482-490.
115. Geary RL, Koyama N, Wang TW, Vergel S, Clowes AW. Failure of heparin to inhibit intimal hyperplasia in injured baboon arteries. The role of heparin-sensitive and -insensitive pathways in the stimulation of smooth muscle cell migration and proliferation. Circulation 1995;91:2972-2981.
116. Kohler TR, Kirkman J, Clowes AW. Effect of heparin on adaptation of vein grafts to arterial circulation. Arteriosclerosis 1989;9:523-528.
117. Brack MJ, Ray S, Chauhan A, et al. The subcutaneus heparin and angioplasty restenosis prevention, SHARP trial. J Am Coll Cardiol 1995;26:947-954.
118. Benazzoug Y, Logeart D, Labat-Robert J, Robert L, Jozefonwicz J, Kern P. Derivatized dextrans modulate collagen synthesis in aortic smooth muscle cells. Biochem Pharmacol 1995;49:847-853.
119. Logeart D, Letourneur D, Jozefonvicz J, Kern P. Collagen synthesis by smooth muscle cells in the presence of antiproliferative polysaccharides. J Biomed Mater Res 1996;30:501-508.
120. Resink TJ, Scott-Burden T, Baur U, Bürgin M, Bühler FR. Decreased susceptibility of cultured smooth muscle cells from SHR rats to growth inhibition by heparin. J Cell Physiol 1989;138:137-144.
121. Morere JF, Letourneur D, Planchon P, et al. Inhibitory effect of substituted dextrans on MCF7 human breast cancer cell growth in vitro. Anti-Cancer Drugs 1992;3:629-634.
122. Bagheri-Yarmand R, Morère JF, Letourneur D, Jozefonvicz J, Israel L, Crépin M. Inhibitory effects of dextran derivatives in vitro on the growth characteristics of premalignant and malignant human mammary epithelial cell lines. Anticancer Res 1992;12:1641-1646.
123. Bagheri-Yarmand R, Bittoun P, Champion J, et al. Carboxymethyl benzylamide dextrans inhibit breast cell growth. In Vitro Cell Dev Biol 1994;30A:822-824.
124. Bagheri-Yarmand R, Liu JF, Ledoux D, Morère JF, Crépin M. Inhibition of human breast epithelial HBL100 cell proliferation by a dextran derivative (CMDB7): interference with the FG2 autocrine loop. Biochem Biophys Res Commun 1997;239:424-428.
125. Bagheri-Yarmand R, Kourbali Y, Mabilat C, et al. The suppression of FGF-2/FGF-4 dependant tumour angiogenesis and growth by the anti-growth factor activity of dextran derivatives (CMDB7). Br J Cancer 1998;78:111-118.
126. Bagheri-Yarmand R, Kourbali Y, Morère JF, Jozefonvicz J, Crépin M. Inhibition of MCF-7 ras tumor growth by carboxymethyl benzylamide dextran: blockage of the paracrine effect and receptor binding of transforming growth factor β1 and platelet-derived growth factor-BB. J Biomed Mater Res 1998; 40:164-169.
127. Jozefowicz M, Jozefonvicz, J. Randomness and biospecificity: random copolymers are capable of biospecific molecular recognition in living systems. Biomaterials 1997;18:1633-1644.
128. San Antonio JD, Lander AD, Wright TC, Karnovsky MJ. Heparin inhibits the attachment and growth of Balb/c-3T3 fibroblasts on collagen substrata. J Cell Physiol 1992; 150:8-16.
129. Anastase S, Letourneur D, Jozefonvicz J. Affinity chromatography of human anti-dextran antibodies. Isolation of two distinct populations. J Chromatogr B Biomed Applic 1996;686: 141-150.